聖湘生物(688289.SH):擬與關聯方產業基金共同投資真邁生物
格隆匯3月7日丨聖湘生物(688289.SH)公佈,爲進一步落實公司戰略規劃,完善公司在基因測序領域的產業鏈佈局,保持綜合競爭力,公司於2025年3月7日召開第二屆董事會2025年第四次臨時會議,審議通過了《聖湘生物科技股份有限公司關於受讓參股公司部分股權並增資暨與關聯方共同投資的議案》。同意公司與關聯方產業基金共同投資真邁生物。其中,公司以自有資金合計投資1.3億元,通過受讓股權及增資交易後,公司對真邁生物的持股比例將由11.903047%增加至15.549381%。
真邁生物專注於基因測序產業上遊設備和試劑的研發製造,擁有包括熒光檢測、核酸修飾、染料合成、酶突變、表面化學工藝等“卡脖子”技術的自研自產能力。雙方的進一步投資合作有助於聖湘生物在基因測序、PCR等分子診斷領域進行更深入的研發和探索,結合聖湘生物在醫療服務、疾病管理等領域的豐富的經驗和資源、以及在感染性疾病檢測等領域的積累,可進一步完善從基礎科研到產品開發再到醫療服務的轉化能力,爲患者提供更全面有效的檢測解決方案,形成一個更加完整和有競爭力的生物醫藥產業鏈。且基因測序領域近年來國產替代進程加速,存在較好的未來市場前景及發展潛力,雙方的戰略合作可推動產品在臨牀應用中的推廣和落地,更好地實現產品的市場價值和商業化,爲患者和醫療領域帶來實質的診療價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.